New Anticoagulants for Atrial Fibrillation

**Magdalena Sobieraj-Teague, M.B.B.S.,¹ Martin O'Donnell, M.B.,¹
and John Eikelboom, M.B.B.S.¹**

The authors regret the following two errors published in the above article in *Seminars in Thrombosis and Hemostasis*, Volume 35, Number 5:

On page 515, line five of the abstract, "These drugs have minimal protein binding and predictable pharmacokinetics that allow fixed dosing without laboratory monitoring and are being compared with vitamin K antagonists or aspirin in phase III clinical trials", is incorrect. This line should read "These drugs have predictable pharmacokinetics that allow fixed dosing without laboratory monitoring, and are being compared with vitamin K antagonists or aspirin in phase III clinical trials".

On page 516, column one, under heading "New Anticoagulants", line three, "The new anticoagulants are all small synthetic molecules with advantages that include minimal protein binding, predictable pharmacokinetics, and fixed dosing without the need for laboratory monitoring", is incorrect. This line should read "The new anticoagulants are all small synthetic molecules with advantages that include predictable pharmacokinetics, and fixed dosing without the need for laboratory monitoring".

¹McMaster University, Hamilton, Ontario, Canada.

Address for correspondence and reprint requests: Dr. Magdalena Sobieraj-Teague, Hamilton General Hospital, Level 7, Room 714, 237 Barton Street East, Hamilton, Ontario, L8L 2X2 Canada (e-mail: teaguem@mcmaster.ca).

Coagulopathies and Thrombosis: Usual and unusual causes and

associations, Part II; Guest Editors, Giuseppe Lippi, M.D., Massimo Franchini, M.D., and Emmanuel J. Favaloro, Ph.D., M.A.I.M.S.

Semin Thromb Hemost 2009;35:711-712. Copyright © 2009 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

DOI 10.1055/s-0029-1242724. ISSN 0094-6176.